journal article·2015-05

A theranostic prodrug delivery system based on Pt(IV) conjugated nano-graphene oxide with synergistic effect to enhance the therapeutic efficacy of Pt drug

Jingwen Li, Zhonglin Lyv, Yanli Li, Huan Liu, Jinkui Wang, Wenjun Zhan, Hong Chen, Huabing Chen, Xinming Li

Biomaterials· Volume 51
Publisher page

Abstract

Due to their high NIR-optical absorption and high specific surface area, graphene oxide and graphene oxide-based nanocomposites have great potential in both drug delivery and photothermal therapy. In the work reported herein we successfully integrate a Pt(IV) complex (c,c,t-[Pt(NH3)2Cl2(OH)2]), PEGylated nano-graphene oxide (PEG-NGO), and a cell apoptosis sensor into a single platform to generate a multifunctional nanocomposite (PEG-NGO-Pt) which shows potential for targeted drug delivery and combined photothermal-chemotherapy under near infrared laser irradiation (NIR), and real-time monitoring of its therapeutic efficacy. Non-invasive imaging using a fluorescent probe immobilized on the GO shows an enhanced therapeutic effect of PEG-NGO-Pt in cancer treatment via apoptosis and cell death. Due to the enhanced cytotoxicity of cisplatin and the highly specific tumor targeting of PEG-NGO-Pt at elevated temperatures, this nanocomposite displays a synergistic effect in improving the therapeutic efficacy of the Pt drug with complete destruction of tumors, no tumor recurrence and minimal systemic toxicity in comparison with chemotherapy or photothermal treatment alone, highlighting the advantageous effects of integrating Pt(IV) with GO for anticancer treatment.
Source: europepmc · Quality: candidate unverified · Source record ↗

Research context

OpenAlex topics: Graphene and Nanomaterials Applications · Nanoparticle-Based Drug Delivery · Nanoplatforms for cancer theranostics

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

References (47)

Show source-provided references
1. Structure, recognition, and processing of cisplatin-DNA adducts10.1021/cr980421n ↗
2. The resurgence of platinum-based cancer chemotherapy10.1038/nrc2167 ↗
3. Understanding platinum-induced ototoxicity10.1016/j.tips.2013.05.006 ↗
4. Nanoscale coordination polymers for platinum-based anticancer drug delivery10.1021/ja803383k ↗
5. Polymer–cisplatin conjugate nanoparticles for acid-responsive drug delivery10.1021/nn9014032 ↗
6. Targeted killing of cancer cells in vivo and in vitro with EGF-directed carbon nanotube-based drug delivery10.1021/nn800551s ↗
7. Fullerenol-cytotoxic conjugates for cancer chemotherapy10.1021/nn900318y ↗
8. The use of biotinylated-EGF-modified gelatin nanoparticle carrier to enhance cisplatin accumulation in cancerous lungs via inhalation10.1016/j.biomaterials.2009.03.010 ↗
9. Platinum (IV)-coordinate polymers as intracellular reduction-responsive backbone-type conjugates for cancer drug delivery10.1016/j.biomaterials.2011.08.022 ↗
10. Biodegradable polymer–cisplatin(IV) conjugate as a pro-drug of cisplatin(II)10.1016/j.biomaterials.2011.06.072 ↗
11. Lipid-coated cisplatin nanoparticles induce neighboring effect and exhibit enhanced anticancer efficacy10.1021/nn403606m ↗
12. Nanocarriers for delivery of platinum anticancer drugs10.1016/j.addr.2013.09.014 ↗
13. Nanoscale drug delivery platforms overcome platinum-based resistance in cancer cells due to abnormal membrane protein trafficking10.1021/nn405004f ↗
14. Gelatin-encapsulated iron oxide nanoparticles for platinum (IV) prodrug delivery, enzyme-stimulated release and MRI10.1016/j.biomaterials.2014.04.029 ↗
15. Near-infrared light-mediated photoactivation of a platinum antitumor prodrug and simultaneous cellular apoptosis imaging by upconversion-luminescent nanoparticles10.1002/ange.201308834 ↗
16. Photosensitive Pt(IV)-azide prodrug-loaded nanoparticles exhibit controlled drug release and enhanced efficacy in vivo10.1016/j.jconrel.2013.10.020 ↗
17. Mechanism of cytotoxicity of anticancer platinum drugs: evidence that cis-diamminedichloroplatinum(II) and cis-diammine-(1,1-cyclobutanedicarboxylato)platinum(II) differ only in the kinetics of their interaction with DNA
18. Review of the comparative pharmacology and clinical activity of cisplatin and carboplatin10.1200/JCO.1999.17.1.409 ↗
19. EGRF conjugated PEGylated nanographene oxide for targeted chemotherapy and photothermal therapy10.1016/j.biomaterials.2013.06.007 ↗
20. Near-infrared light-mediated nanoplatforms for cancer thermo-chemotherapy and optical imaging10.1002/adma.201301890 ↗
21. Drug delivery with PEGylated MoS2 nano-sheets for combined photothermal and chemotherapy of cancer10.1002/adma.201305256 ↗
22. Engineered, self-assembled near-infrared photothermal agents for combined tumor immunotherapy and chemo-photothermal therapy10.1016/j.biomaterials.2014.04.073 ↗
23. Nano-graphene oxide for cellular imaging and drug delivery10.1007/s12274-008-8021-8 ↗
24. Synergistic effect of chemo-photothermal therapy using PEGylated graphene oxide10.1016/j.biomaterials.2011.07.071 ↗
25. A review of optical imaging and therapy using nanosized graphene and graphene oxide10.1016/j.biomaterials.2013.08.066 ↗
26. Graphene oxide mediated delivery of methylene blue for combined photodynamic and photothermal therapy10.1016/j.biomaterials.2013.04.066 ↗
27. Multifunctional PEG-GO/CuS nanocomposites for near-infrared chemo-photothermal therapy10.1016/j.biomaterials.2014.04.008 ↗
28. Structure-dependent photothermal anticancer effects of carbon-based photoresponsive nanomaterials10.1016/j.biomaterials.2014.01.043 ↗
29. Targeted theranostic platinum(IV) prodrug with a built-in aggregation-induced emission light-up apoptosis sensor for noninvasive early evaluation of its therapeutic responses in situ10.1021/ja411811w ↗
30. Carboxylation of kinetically inert platinum(IV) hydroxy complexes. An entree into orally active platinum(IV) antitumor agents10.1021/ic00109a004 ↗
31. A prodrug strategy to deliver cisplatin(IV) and paclitaxel in nanomicelles to improve efficacy and tolerance10.1016/j.biomaterials.2012.05.049 ↗
32. The use of polymeric platinum(IV) prodrugs to deliver multinuclear platinum(II) drugs with reduced systemic toxicity and enhanced antitumor efficacy10.1016/j.biomaterials.2012.08.015 ↗
33. Graphene oxide-peptide conjugate as an intracellular protease sensor for caspase-3 activation imaging in live cells10.1002/anie.201101351 ↗
34. PEGylated nanographene oxide for delivery of water-insoluble cancer drugs10.1021/ja803688x ↗
35. Caspases: the executioners of apoptosis10.1042/bj3260001 ↗
36. Glutathione-ascorbic acid antioxidant system in animals10.1016/S0021-9258(17)36891-6 ↗
37. Synthesis and characterization of Pt(IV) fluorescein conjugates to investigate Pt(IV) intracellular transformations10.1021/bc400281a ↗
38. Apoptosis. Its significance in cancer and cancer therapy10.1002/1097-0142(19940415)73:8<2013::AID-CNCR2820730802>3.0.CO;2-J ↗
39. Apoptotic pathways: the roads to ruin10.1016/S0092-8674(00)81728-6 ↗
40. Caspases: enemies within10.1126/science.281.5381.1312 ↗
41. Hyperthermic effects of gold nanorods on tumor cells10.2217/17435889.2.1.125 ↗
42. Enhancing the toxicity of cancer chemotherapeutics with gold nanorod hyperthermia10.1002/adma.200800921 ↗
43. Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review10.1016/S0168-3659(99)00248-5 ↗
44. Near infrared laser induced targeted cancer therapy using thermo-responsive polymer encapsulated gold nanorods10.1021/ja412735p ↗
45. Cisplatin neuropathy. Clinical, electrophysiologic, morphologic, and toxicologic studies10.1002/1097-0142(19841001)54:7<1269::AID-CNCR2820540707>3.0.CO;2-9 ↗
46. High-dose cisplatin treatment: hearing loss and plasma concentrations10.1288/00005537-199007000-00008 ↗
47. Platinum organ toxicity and possible prevention in patients with testicular cancer10.1002/(SICI)1097-0215(19991210)83:6<866::AID-IJC34>3.0.CO;2-9 ↗